Deals
Cloud Technology Solutions (CTS) has merged with application development and machine learning specialist Qlouder in a deal that creates the what the companies say is the largest dedicated Google Cloud practice in Europe.
The merger will see the creation of a 150-strong team offering unrivalled expertise in app development, data science and machine learning.
The business will operate from offices in the UK and Netherlands, enabling it to significantly expand its services across the continent.
It will provide a unique end-to-end full-service offering for the Google Cloud proposition including, application development, machine learning, big data analytics, cloud migration
Noerr has advised the French state-owned banking group Caisse des dépôts (CDC) and public transport provider Transdev, on structuring a transnational partnership with the German group Rethmann.
In connection with Veolia’s planned exit from Transdev, Rethmann is planning to acquire a stake in the company. At the same time, Rethmann is to contribute its German public transport division, which is bundled in Rhenus Veniro, to Transdev.
Once the transaction has been completed, Rethmann is to hold 34 per cent of the capital in Transdev, while CDC is to control the company with two-thirds of voting rights and 66 per
Foresight Group (Foresight) has made a GBP500,000 equity investment into Mobile Pay Systems, trading as Swoopos through the Midlands Engine Investment Fund (MEIF).
Swoopos provides a Mobile Point of Sale (“MPOS”) universal payments system that combines ePOS and cloud-based technology to deliver rich data analysis for businesses operating in the hospitality, and, soon the retail sector. The system includes a mobile wallet, booking system and mobile ordering, as well as a management reporting suite to help the retailer capture and monitor customer data.
Swoopos launched in August 2017 and already has 200+ systems installed with well-known brands including Costa
Aurelius Equity Opportunities is to acquire VAG, the Mannheim-based manufacturer of water and waste water valves from US-based Rexnord.
With approximately 1,200 employees, VAG generated sales of almost EUR200 million in its 2017/18 financial year. The transaction is to be finalised in Q4 2018.
As a globally active company, VAG is one of the leading suppliers of valves for water treatment and distribution, waste water management, dams, power stations and the energy industry. VAG is known and appreciated throughout the world for its market-leading know-how in product development and bears the quality seal “Engineering made in Germany”. The company
Le Col, a British producer of technical performance cycling apparel, has raised GBP2.35 million from Puma Private Equity to fuel further growth, with the opportunity to increase investment to GBP3.5 million.
Le Col, founded by ex-professional cyclist Yanto Barker in 2011, has its DNA in the pro peloton and its products have been bringing performance kit to consumers with a quality once reserved solely for professionals. The British company is based in London but manufactures all its kit in its own factory in Treviso, Italy – an area renowned for expertise in high-performance sporting apparel and the latest technical materials.
Venture capital firm Truffle Capital’s newly-created startup company Nanosive SAS, has signed an exclusive global licence agreement with Yale University, giving Nanosive worldwide and exclusive rights to develop and exploit a technological platform for a wide range of applications in dermo-cosmetics, in particular sun protection, the prevention of cancer and ageing of the skin.
Truffle Capital, which focuses on creating and financing start-ups with disruptive technologies in life sciences and information technology, invested in Nanosive through its new Truffle BioMedTech Fund which has already collected USD102 million and its Truffle Innove FRR France fund.
The licenced technology is based
Severstal Ventures, which was set up by steel and mining company PAO Severstal to support venture projects developing new production technologies and materials, has invested in Chrysalix RBV GP Ltd. (Chrysalix RoboValley).
Chrysalix RoboValley was set up to invest in intelligent systems and automation platforms, including areas such as artificial intelligence (AI), robotics, machine learning, Internet of things (IoT), as well as the development of new materials and special technologies that will enable the digital transformation of large industrial companies. According to Chrysalix RoboValley, the fund’s main investments will be in projects developed in Europe, North America and Asia.
Q3 2018 saw 3,894 venture capital-backed deals announced worth a total of USD69 billion, according to data released by Preqin. This brings total year-to-date deal making to USD195 billion, meaning that the first three quarters of 2018 have already surpassed 2017’s full-year record of USD189 billion in venture capital deals.
Private equity deals meanwhile saw something of a slow-down with 1,205 private equity-backed buyout deals announced in Q3, worth a combined USD93 billion. Preqin expects these figures to rise by up to 5 per cent as more information becomes available, but nonetheless the quarter seems unlikely to match the USD129
Spanish ice cube manufacturer Procubitos Europe, which is owned by GED and Grupo Hervaz, has acquired a 60 per cent stake in Italian company Polo Nord.
Located in the province of Verona, between Milan and Venice, Polo Nord will meet the demand of the group both in Italy and its neighbouring countries, such as Switzerland or Austria, with the ice produced in its factory. The company is currently capable of producing 25 tons/day of Vogt ice and has the most advanced technology in the ice manufacturing market. As part of an ambitious development strategy, the group also has important investment
Blackstone has agreed to acquire Clarus, a global life sciences investment firm that has raised USD2.6 billion since its founding.
Clarus, with offices in the life sciences hubs of Boston and San Francisco, is focused on funding growth-stage investments, often in partnership with major biopharmaceutical companies through R&D collaborations. These investments bring to market promising new medicines that improve patients’ lives.
Clarus is led by a team of seasoned experts who have invested in more than 50 companies in the biopharmaceutical, medical device and diagnostic sectors – as well as across multiple disease areas, primarily in the oncology space.
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
